Associated Papers
Complement factor I: Regulatory nexus, driver of immunopathology, and therapeutic.
Hallam TM et al.
Immunobiology, 2023
Effect of rare coding variants in the CFI gene on Factor I expression levels.
de Jong S et al.
Human Molecular Genetics, 2020
Genotype-phenotype correlations of low-frequency variants in the complement system in renal disease and age-related macular degeneration.
Geerlings MJ et al.
Clinical Genetics, 2018
29888403 (PubMed )
Supplement: CGE-94-330-s001.zip › Appendix_S1 › Table_S4.xlsx › CFI
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Greenbaum LA et al.
Kidney International, 2016
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.
Noris M et al.
Blood, 2014
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.
Fremeaux-Bacchi V et al.
Clinical Journal of the American Society of Nephrology : Cjasn, 2013
Complement factor I in health and disease.
Nilsson SC et al.
Molecular Immunology, 2011
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.
Fakhouri F et al.
Journal of the American Society of Nephrology : Jasn, 2010
Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome.
Bienaime F et al.
Kidney International, 2010
Select a paper to view details